Journal of Diabetes and Its Complications
Volume 18, Issue 6 , Pages 367-376 , November 2004

The role of glimepiride in the effective management of Type 2 diabetes

Received 31 December 2003 ,Accepted 7 July 2004.

References 

  1. Alvarsson M, Sundkvist G, Lager I, Henricsson M, Berntorp K, Fernqvist-Forbes E, et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed Type 2 diabetic patients. Diabetes Care. 2003;26:2231–2237
  2. American College of Endocrinology, American Association of Clinical Endocrinologists. American College of Endocrinology consensus statement on guidelines for glycemic control. Endocrine Practice. 2002;8(Suppl 1):5–11
  3. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003;26(Suppl 1):S33–S50
  4. American Diabetes Association. Clinical practice recommendations 2003. Diabetes Care. 2003;26(Suppl 1):S1–S156
  5. Bavirti S, Tayek JA. Low-dose oral glyburide reduces glucose production rates in patients with impaired fasting glucose. Metabolism. 2003;52:407–412
  6. Berelowitz M, Fischette C, Cefalu W, Schade DS, Sutfin T, Kourides IA. Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM. Diabetes Care. 1994;17:1460–1464
  7. Bijlstra PJ, Lutterman JA, Russel FGM, Thien T, Smits P. Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans. Diabetologia. 1996;39:1083–1090
  8. Brady PA, Terzic A. The sulfonylurea controversy: more questions from the heart. Journal of the American College of Cardiology. 1998;31:950–956
  9. Bugos C, Austin M, Atherton T, Viereck C. Long-term treatment of Type 2 diabetes mellitus with glimepiride is weight neutral: a meta-analysis. abstract Diabetes Research and Clinical Practice. 2000;50(Suppl 1):S47
  10. Campbell RK. Glimepiride: role of a new sulfonylurea in the treatment of Type 2 diabetes mellitus. Annals of Pharmacotherapy. 1998;32:1044–1052
  11. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates on diabetes. Available at: www.cdc.gov/diabetes/pubs/estimates.htm2002;Accessed October 24, 2003
  12. Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patients. Diabetic Medicine. 2001;18:828–834
  13. Cohen KL, Harris S. Efficacy of glyburide in diabetics poorly controlled on first generation oral hypoglycemics. Diabetes Care. 1987;10:555–557
  14. In:  DeFronzo R editors. Current therapy of diabetes mellitus. 1st ed. St. Louis, MS: Mosby-Year Book; 1997;
  15. DeFronzo RA, Goodman AM for the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. New England Journal of Medicine. 1995;333:541–549
  16. Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for Type 2 diabetes. Southern Medical Journal. 2002;95:68–71
  17. Dills DG, Schneider J for the Glimepiride/Glyburide Research Group. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Hormone and Metabolic Research. 1996;28:426–429
  18. Draeger KE, Wernicke-Panten K, Lomp H-J, Schüler E, Roßkamp R. Long-term treatment of Type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl®): a double-blind comparison with glibenclamide. Hormone and Metabolic Research. 1996;28:419–425
  19. Edelman SV, Henry RR. Insulin therapy for normalizing glycosylated hemoglobin in Type II diabetes: application, benefits, and risks. Diabetes Reviews. 1995;3:308–334
  20. Ferrari R, Ceconi C, Curello S, Percoco G, Toselli T, Antonioli G. Ischemic preconditioning, myocardial stunning, and hibernation: basic aspects. American Heart Journal. 1999;138(Suppl):S61–S68
  21. Gatmendia F, Fragoso A The Study Group on Glimepiride of the Andean Countries. Clinical prospective Latino American experience with glimepiride in the treatment of diabetes mellitus Type 2. (abstract P256) Diabetes Research and Clinical Practice. 2000;50(Suppl):S48
  22. Geisen K, Vegh A, Krause E, Papp JG. Cardiovascular effects of conventional sulfonylureas and glimepiride. Hormone and Metabolic Research. 1996;28:496–507
  23. Goldberg RB, Holvey SM, Schneider J for the Glimepiride Protocol #201 Study Group. A dose-response study of glimepiride in patients with NlDDM who have previously received sulfonylurea agents. Diabetes Care. 1996;19:849–856
  24. González JU, Dutron CD. Glimepiride: its action on body weight and lipid profile in Type II diabetes mellitus: prospective clinical experiment in Latin-America. Tribuna Médica. 1999;84:151–158
  25. Gregorio F, Ambrosi F, Cristallini S, Filipponi P, Santeusanio F. Effects of glimepiride on insulin and glucagon release from isolated rat pancreas at different glucose concentrations. Acta Diabetologica. 1996;33:25–29
  26. Harrower AD. Efficacy of gliclazide in comparison with other sulphonylureas in the treatment of NIDDM. Diabetes Research and Clinical Practice. 1991;14(Suppl 2):S65–S67
  27. Holstein A, Plaschke A, Egberts E-H. Lower incidence of severe hypoglycaemia in patients with Type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes and Metabolism Research and Reviews. 2001;17:467–473
  28. Jeppesen J, Zhou M-Y, Chen Y-DI, Reaven GM. Effect of glipizide treatment on postprandial lipaemia in patients with NIDDM. Diabetologia. 1994;37:781–787
  29. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in Type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Archives of Internal Medicine. 1996;156:259–264
  30. Kappel C, Dills DG. Type 2 diabetes: update on therapy. Comprehensive Therapy. 1998;24:319–326
  31. Kitabchi AE, Kaminska E, Fisher JN, Sherman A, Pitts K, Bush A, et al. Comparative efficacy and potency of long-term therapy with glipizide or glyburide in patients with Type 2 diabetes mellitus. American Journal of the Medical Sciences. 2000;319:143–148
  32. Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker KH, et al. Sulfonylureas and ischaemic preconditioning: a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. European Heart Journal. 1999;20:439–446
  33. Knirsch W, Herrmann M, Krauth RA. Glimepiride (Amaryl®)—Results of a non-interventional study. (abstract P1374) Diabetes Research and Clinical Practice. 2000;50(Suppl):S346
  34. Korytkowski M, Thomas A, Reid L, Tedesco MB, Gooding WE, Gerich J. Glimepiride improves both first and second phases of insulin secretion in Type 2 diabetes. Diabetes Care. 2002;25:1607–1611
  35. Kramer W, Muller G, Girbig F, Gutjahr U, Kowalewski S, Hartz D, et al. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor: II. Photoaffinity labeling of a 65 kDa protein by [3H]glimepiride. Biochimica et Biophysica Acta. 1994;1191:278–290
  36. Kramer W, Muller G, Girbig F, Gutjahr U, Kowalewski S, Hartz D, et al. The molecular interaction of sulfonylureas with beta-cell ATP-sensitive K(+)-channels. Diabetes Research and Clinical Practice. 1995;28(Suppl):S67–S80
  37. Langtry HD, Balfour JA. Glimepiride: a review of its use in the management of Type 2 diabetes mellitus. Drugs. 1998;55:563–584
  38. Massi-Benedetti M, Herz M, Pfeiffer C. The effects of acute exercise on metabolic control in Type II diabetic patients treated with glimepiride or glibenclamide. Hormone and Metabolic Research. 1996;28:451–455
  39. Matsumoto K, Sera Y, Abe Y, Tominaga T, Ueki Y, Miyake S. Combination therapy of alpha-glucosidase inhibitor and a sulfonylurea compound prolongs the duration of good glycemic control. Metabolism. 2002;51:1548–1552
  40. Melander A, Bitzén PO, Faber O, Groop L. Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use. Drugs. 1989;37:58–72
  41. Mitrakou A, Vuorinen-Markkola H, Raptis G, Toft I, Mokan M, Strumph P, et al. Simultaneous assessment of insulin secretion and insulin sensitivity using a hyperglycemia clamp. Journal of Clinical Endocrinology and Metabolism. 1992;75:379–382
  42. Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation. 2001;103:3111–3116
  43. Müller G, Hartz D, Pünter J, Ökonomopulos R, Kramer W. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor: I. Binding characteristics. Biochimica et Biophysica Acta. 1994;1191:267–277
  44. O'Brien RC, Luo M. The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro. Metabolism. 1997;46(12 Suppl 1):22–25
  45. Pfeifer MA, Halter JB, Porte D. Insulin secretion in diabetes mellitus. American Journal of Medicine. 1981;70:579–588
  46. Rendell MS, Glazer NB, Ye Z. Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: influence of prior antidiabetic drug regimen. Journal of Diabetes and its Complications. 2003;17:211–217
  47. Riccio A, Lisato G, Vigili De Kreutzenberg S, Marchetto S, Turrin M, Tiengo A, et al. Gliclazide potentiates suppression of hepatic glucose production in non-insulin-dependent diabetic patients. Metabolism. 1996;45:1196–1202
  48. Riddle MC. Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine. Hormone and Metabolic Research. 1996;28:430–433
  49. Riddle MC. Tactics for Type II diabetes. Endocrinology and Metabolism Clinics of North America. 1997;26:659–677
  50. Riddle M, McDaniel P, Bugos C. First-dose C-peptide response and risk of hypoglycemia are lower with glimepiride than glyburide. (abstract) Diabetes Care. 2001;50(Suppl 2):A129
  51. Riddle MC, Schneider J for the Glimepiride Combination Group. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Diabetes Care. 1998;21:1052–1057
  52. In:  Rifkin H editors. The physician's guide to Type II diabetes (NIDDM): diagnosis and treatment. Alexandria, VA: American Diabetes Association; 1985;
  53. Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia. 1996;39:1617–1624
  54. Rosenstock J. Management of Type 2 diabetes mellitus in the elderly: special considerations. Drugs and Aging. 2001;18:31–44
  55. Rosenstock J, Samols E, Muchmore DB, Schneider J for the Glimepiride Study Group. Glimepiride, a new once-daily sulfonylurea: a double-blind placebo-controlled study of NIDDM patients. Diabetes Care. 1996;19:1194–1199
  56. Schade DS, Jovanovic L, Schneider J. A placebo-controlled, randomized study of glimepiride in patients with Type 2 diabetes mellitus for whom diet therapy is unsuccessful. Journal of Clinical Pharmacology. 1998;38:636–641
  57. Scholz GH, Schneider K, Knirsch W, Becker G. Efficacy and tolerability of glimepiride in daily practice: a non-interventional observational cohort study. Clinical Drug Investigation. 2001;21:597–604
  58. Schreiber SA, Russmann A. Improved metabolic control with a favorable weight profile in patients with Type 2 diabetes treated with insulin glargine in clinical practice. (abstract 464-P) Diabetes. 2002;51(Suppl 2):A114
  59. Siconolfi-Baez L, Banerji MA, Lebovitz HE. Characterization and significance of sulfonylurea receptors. Diabetes Care. 1990;13(Suppl 3):2–8
  60. Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT the Glipizide Gastrointestinal Therapeutic System Study Group. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM: results of two multicenter, randomized, placebo-controlled clinical trials. Diabetes Care. 1997;20:597–606
  61. Sobol AB, Drzewoski J. The effect of glimepiride on some haemostatic parameters in patients with Type 2 diabetes mellitus. (abstract P252) Diabetes Research and Clinical Practice. 2000;50(Suppl):S47
  62. Sonnenberg GE, Garg DC, Weidler DJ, Dixon RM, Jaber LA, Bowen AJ, et al. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus. Annals of Pharmacotherapy. 1997;31:671–676
  63. The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine. 1993;329:977–986
  64. Turner R, Cull C, Holman R for the United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in none insulin-dependent diabetes mellitus. Annals of Internal Medicine. 1996;124(1 pt 2):136–145
  65. UKPDS Group. UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting Type II diabetic patients. Metabolism. 1990;39:905–912
  66. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of Type II diabetes: a progressive disease. Diabetes. 1995;44:1249–1258
  67. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  68. Winkler F, Teich G, Irsigler K. Österreichische Glimepirid Multicenter-Studie. (abstract) Diabetes Stoffwechsel. 1998;7(Suppl 1):68
  69. World Health Organization. WHO information fact sheets: Diabetes mellitus. Available at: http:www.who.int/inf-fs/fact138.html2002;Accessed October 23, 2003
  70. Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR for the UK Prospective Diabetes Study Group. Sulfonylrea inadequacy: efficacy of addition of insulin over 6 years in patients with Type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330–336

PII: S1056-8727(04)00078-9

doi: 10.1016/j.jdiacomp.2004.07.001

Journal of Diabetes and Its Complications
Volume 18, Issue 6 , Pages 367-376 , November 2004

Article Tools

* Image Usage & Resolution